Fuse Launches Flip Product Range for Rapid Point-of-Need Diagnostics
First product Flip Mycoplasma detects cell culture contamination with unrivalled speed, accuracy and simplicity
CARB-X Funds Fuse to Develop Innovative, Instrument-Free Diagnostic for Chlamydia and Drug-Resistant Gonorrhoea
Award to fund development and characterization of assays for Chlamydia trachomatis and Neisseria gonorrhoeae to integrate into low-cost, instrument-free diagnostic.
Fuse raises £1.6m seed funding to develop innovative point-of-need diagnostic tests
Fuse Diagnostics has today announced that it has completed an oversubscribed seed investment round – raising a total of £1.6 million from a syndicate of angel investors and innovation agency Innovate UK.